Potentiating hypergastrinemic effect by the peroxisome proliferator ciprofibrate and omeprazole in the rat

Scandinavian Journal of Gastroenterology

Volumn 33, Issue 6, 1998, Pages 595-599

  Hammer, T A ^a   Sandvik, A K ^a   Waldum, H L ^a,b  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

Author keywords

Ciprofibrate; Gastric acidity; Gastrin; Peroxisome proliferators; Proton pump inhibitors; Somatostatin

Indexed keywords

CIPROFIBRATE; GASTRIN; OMEPRAZOLE; RNA; SOMATOSTATIN;

ANIMAL EXPERIMENT; ARTICLE; DRUG EFFECT; ENTEROCHROMAFFIN CELL; FEMALE; GASTRIN BLOOD LEVEL; HORMONE DETERMINATION; HORMONE RELEASE; HYPERGASTRINEMIA; NONHUMAN; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RAT; RNA PROBE; STOMACH ACID SECRETION; STOMACH PH;

ANIMALS; ANTI-ULCER AGENTS; ANTILIPEMIC AGENTS; CLOFIBRIC ACID; DRUG INTERACTIONS; ENTEROCHROMAFFIN-LIKE CELLS; FEMALE; GASTRIC MUCOSA; GASTRINS; MICROBODIES; OMEPRAZOLE; RATS; RNA, MESSENGER; SOMATOSTATIN;

EID: 0031836133     PISSN: 00365521     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365529850171855     Document Type: Article

References (24)

1. Moody DE, Reddy JK, Lake BG, Popp JA, Reese DH. Peroxisome proliferation and nongenotoxic carcinogenesis: commentary on a symposium. Fund Appl Toxicol 1991;16: 233-48.
2. Reddy JK, Azarnoff DL, Hignite CE. Hypolipidaemic hepatic peroxisome proliferators form a novel class of chemical carcinogens. Nature 1980;283:397-8.
3. Brien MLO, Rangwala SM, Henry KW, Weinberger C, Crick DC, Waechter CJ, et al.. Convergence of three steroid receptor pathways in the mediation of nongenotoxic hepatocarcinogenesis. Carcinogenesis 1996;2:185-90.
4. Spencer AJ, Barbolt TA, Henry DC, Eason CT, Sauerschell RJ, Bonner FW. Gastric morphological changes including carcinoid tumours in animals treated with a potent hypolipidaemic agent, ciprofibrate. Toxicol Pathol 1989;17:7-15.
5. Eason CT, Spencer AJ, Pattison A, Howells DD, Henry DC, Bonner FW. Species variation in gastric toxicity following chronic administration of ciprofibrate to rat, mouse and marmoset. Toxicol Appl Pharmacol 1988;95:328-38.
6. Creutzfeldt W, Stöckmann F, Conlon JM, Folsch UR, Bonatz G, Wulfrath M. Effect of short- and long-term feeding of omeprazole on rat gastric endocrine cells. Digestion 1986;35 Suppl 1:84-97.
7. Walsh JH, Richardson CT, Fordtran JS. pH dependence of acid secretion and gastrin release in normal and ulcer subjects. J Clin Invest 1975;55:462-8.
8. Eason CT, Pattison A, Howell DD, Bonner FW. The effect of ciprofibrate on gastric secretion in the rat. J Pharm Pharmacol 1988;40:512-3.
9. Martinsen TC, Nesjan N, Rønning K, Sandvik AK, Waldum HL. The peroxisome-proliferator ciprofibrate induced hypergastrinemia without raising gastric pH. Carcinogenesis 1996;10:101-3.
10. Larsson H, Carlsson E, Ryberg B, Fryklund J, Wallmark B. Rat parietal cell function after prolonged inhibition of gastric acid secretion. Am J Physiol 1988;254:G33-9.
11. Kleveland PM, Haugen SE, Waldum HL. The preparation of bioactive I-gastrin, using iodo-gen as oxidizing agent, and the use of this tracer in receptor studies. Scand J Gastroenterol 1985;20:569-76.
12. Rehfeld JF. A unique high-titer antiserum to gastrin. Scand J Clin Lab Invest 1981;41:723-7.
13. Goodman RH, Aron DC, Roos BA. Rat pre-pro-somatostatin. Structure and processing by microsomal membranes. J Biol Chem 1983;258:5570-3.
14. Fuller PJ, Stone DL, Brand SJ. Molecular cloning and sequencing of rat preprogastrin complementary deoxiribonucleic acid. Mol Endocrinol 1987;1:306-10.
15. Arcari P, Martinelli R, Salvatore F. The complete sequence of a full-length cDNA for human liver glyceraldehyde-3-phosphatase dehydrogenase: evidence for multiple mRNA species. Nucl Acid Res 1984;12:9179-89.
16. Lichtenberger LM. Importance of food in the regulation of gastrin release and formation. Am J Physiol 1982;243:G429-41.
17. Holst JJ, Ørskov C, Seier-Poulsen S. Somatostatin is an essential paracrine link in acid inhibition of gastrin secretion. Digestion 1992;51:95-102.
18. Waldum HL, Brenna E, Kleveland PM, Sandvik AK. Gastrin - physiological and pathophysiological role: clinical consequences. Dige Dis 1995;13:25-38.
19. Gavey CJ, Smith JTL, Nwokolo CU, Pounder RE. Clofibrate raises human 24 h intragastric acidity but does not affect plasma gastrin concentration. Br J Clin Pharmacol 1990;29:473-7.
20. Lind T, Cederberg C, Idström J-P, Lönroth H, Olbe L, Lundell T. 24-hour intragastric acidity and plasma gastrin during long-term treatment with omeprazole or ranitidine in patients with reflux esophagitis. Scand J Gastroenterol 1991;26:620-6.
21. Waldum HL, Arnestad JS, Brenna E, Eide I, Syversen U, Sandvik AK. Marked increase in gastric acid secretory capacity after omeprazole treatment. Gut 1996;39:649-53.
22. +-ATPaSe activity. J Biol Chem 1985;260:13681-4.
23. Waldum HL, Kvetnoi IM, Sylte R, Schulze B, Martinsen TC, Sandvik AK. The effect of the peroxisome proliferator ciprofibrate on the gastric mucosa and particularly the gastrin (G) cell. J Molec Endocrinol 1998;20:111-7.
24. Sandvik AK, Dimaline R, Forster ER, Evans D, Dockray GJ. Differential control of somatostatin messenger RNA in rat gastric corpus and antrum. Role of acid, food, and capsaicin-sensitive afferent neurons. J Clin Invest 1993;91:244-50.